b Tested in sodium chloride 0.9%.
c Test performed using the formulation WITHOUT edetate disodium.
d Refer to Appendix for the composition of parenteral nutrition solutions. TPN indicates a 2-in-1 admixture.
e Tested in Ringer’s injection, lactated.
f Tested in dextrose 5% in sodium chloride 0.225%.
g Piperacillin component. Piperacillin in an 8:1 fixed-ratio concentration with tazobactam.
h Imipenem component. Imipenem in a 1:1 fixed-ratio concentration with cilastatin.
i Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.
j Tested in both dextrose 5% and sodium chloride 0.9%.
k Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.
m Imipenem component. Imipenem in a 2:2:1 fixed-ratio concentration with cilastatin and relebactam.
n Tested with sodium thiosulfate (CAN) 4 mg/mL.
o Tested with sodium nitroprusside (MIC) 400 mcg/mL.
p Tested as the premixed infusion solution.
q As epinephrine base rather than the salt.
s Bitartrate salt of epinephrine tested.
t Tested with epinephrine bitartrate (MPI) 60 mcg/mL.
u Tested with sildenafil (PF) 0.8 mg/mL.
v Tested with norepinephrine bitartrate (HOS) 60 mcg/mL.
w Tested with vasopressin (FRK) 0.4 units/mL.
x Tested in sodium chloride 0.45%.
y Tested with epinephrine (PAR) 16 mcg/mL in dextrose 5%.
z Tested with epinephrine (PAR) 64 mcg/mL in dextrose 5%.
aa Tested with calcium chloride (IMS) 100 mg/mL.
bb Tested with calcium chloride (IMS) 20 mg/mL in dextrose 5%.
cc Tested with heparin sodium (HOS) 2 units/mL premixed infusion solution in sodium chloride 0.9%.
dd Tested with heparin sodium (HOS) 100 units/mL premixed infusion solution in sodium chloride 0.45%.
ee Tested with vasopressin (PAR) 0.2 unit/mL in dextrose 5%.
ff Tested with vasopressin (PAR) 1 unit/mL in dextrose 5%.
ii Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.
jj Subvisible particulate test methods include light obscuration, flow imaging microscopy, and backgrounded membrane imaging.